cases shared unique morphologic features (deeply invaginated nuclear membranes, scant cytoplasm with fine azurophilic granularity, and finely granular Sudan black B and myeloperoxidase cytochemical reactivity) that were remarkably similar t o those of acute promyelocytic leukemia (APL); particularly the microgranular variant (FAB AML-M3v). However, all 20 cases lacked the t(15;17) and 17 cases tested lacked the promyelocyticlretinoic acid receptor (Y (RARru)
CUTE MYELOID LEUKEMIA (AML)
constitutes a heterogeneous group of leukemic disorders with diverse biologic and clinical features. Traditionally, AML has been classified by morphologic and cytochemical criteria, fusion transcript in RT-PCR assays; 12 cases had 46,XX or 46,XY karyotypes, whereas 2 cases had abnormalities of chromosome 17q: 1 with de1(17)(q25) and the other with t(11;17)(q23;q21) and the promyelocytic leukemia zinc finger/RARa fusion transcript. All cases tested (6/20), including the case with t(11;17), failed t o differentiate in vitro in response t o all-trans retinoic acid (ATRA), suggesting that these cases may account for some APLs that have not shown a clinical response t o ATRA. Four of 6 cases tested showed functional NK cell-mediated cytotoxicity, suggesting a relationship between these unique CD33' . CD56' .
CD16-acute leukemias and normal CD56' . CD16-NK precursor cells. Using a combination of panning and multiparameter flow cytometric sorting, we identified a normal CD56' . CD33' . CD16-counterpart cell at a frequency of 1% t o 2% in the peripheral blood of healthy individuals. Our studies suggest that this form of acute leukemia may arise from transformation of a precursor cell common to both the myeloid and NK cell lineages; thus we propose the designation myeloid/NK acute leukemia. Recognition of this new leukemic entity will be important in distinguishing these ATRA-nonresponsive cases from ATRA-responsive true APL. formalized in the French-American-British (FAB) classification ~y s t e m . "~ However, more recent analyses of the immunophenotypic, cytogenetic, molecular, and cellular features of AML blasts have identified unique biologic subsets of AML."'' Assessment of these biologic parameters is now allowing for more precise diagnosis, classification, and more accurate prognostication of AML patients; moreover, these biologic and genetic parameters are beginning to have a significant impact on therapeutic decision making.'"' From a series of 350 consecutive adult de novo AML patients (initially identified by morphologic and cytochemical criteria) who were candidates for Southwest Oncology Group (SWOG) treatment protocols, we identified 20 cases of a previously unrecognized form of acute leukemia. These 20 cases were distinguished by their lack of expression of HLA-DR and by their unusual coexpression of myeloid and natural killer (NK) cell-associated antigens. Although the morphologic features of these cases were inconsistently classified by submitting SWOG institutions, the majority of cases were noted upon review to bear a striking morphologic and immunophenotypic resemblance to AML cases of the FAB-M3 subtype, particularly the microgranular variant (M3v). In this report, we fully characterize the morphologic, immunophenotypic, cytogenetic, molecular, and biologic features of this unique type of acute leukemia. Our finding that these leukemia cases show functional NK cell-type mediated cytotoxicity and our identification of a normal myeloid/NK counterpart cell in the peripheral blood of healthy individuals suggest that this unique form of acute leukemia may arise from transformation of a precursor cell common to the myeloid and NK cell lineages.
MYELOID/NATURAL KILLER CELL ACUTE

LEUKEMIA MATERIALS AND METHODS
Sample acquisition and morphologic review.
This study was based on specimens of bone marrow (BM) or peripheral blood (PB) submitted to the SWOG Reference Laboratory and Myeloid Repository at the UNM Cancer Center according to standard procedures of SWOG. Briefly, pretreatment specimens of BM andor PB are submitted to the Repository for patients who are candidates for SWOG AML treatment studies. Upon initial receipt, leukemic blasts are enriched on Ficoll-Hypaque gradients (Pharmacia, Piscataway, NJ) and the leukemic blast percentage is determined by analysis of Wright-stained cytospins. All cases are immediately analyzed for the expression of a panel of hematopoietic cell surface antigens using multicolor flow cytometry. Residual leukemic cells are cryopreserved as sterile, viable cell suspensions at -135°C; these cryopreserved specimens were used for the additional biologic assays undertaken in this study.
Pretreatment Wright-stained BM aspirates and PB specimens as well as a panel of submitted or centrally performed cytochemical stains (Sudan black B [SBB], alpha napthyl butyrate esterase, myeloperoxidase [MPO] , and chloracetate esterase) were reviewed by members of the SWOG Leukemia Review Panel. Additional morphologic and cytochemical studies were also performed on air-dried aspirates and on thawed, previously cryopreserved cell suspensions and were reviewed by three of the authors (AS., D.H., C.W.) and Dr Kathy Foucar (University of New Mexico, Albuquerque, NM). All cases were classified using standard FAB criteria and were alternatively classified as myeIoidNK acute leukemia if they had a distinct set of reproducible morphologic and cytochemical features different from those detailed in the current FAB classification system (see ResuIts).l4 Three cases reported in this study were ultimately not registered on a SWOG clinical trial (Table l ; Cases 12, 14, and 15); however, slides from each case were submitted by SWOG institutional pathologists and underwent an identical process of morphologic review.
Immunophenotypic/fiow cytometric analysis. The cell surface antigen profile of leukemic blasts in each case initially were determined on fresh cells at the time of sample submission using standard two-color flow cytometric analysis with a panel of monoclonal antibodies (MoAbs) as previously de~cribed.'~"~ The mononuclear cell component after Ficoll-Hypaque gradient separation was washed, then incubated in staining media with directly-conjugated [either fluorescein isothiocyanate (FITC) or phycoerythrin (PE)] MoAbs for 30 minutes at 4°C [Leu19 (CD56), MY10 (CD34), LeuMl (CDlS), Leu1 la (CD16), Leu12 (CD19). Leu16 (CD20). Leu5b (CD2), CR1 (CD35), CDIla, LeuMS (CDllc), GpIIbflIIa (CD41). Leu 5b (CD2), Leu4 (CD3). and HLA-DR (all supplied by Becton Dickinson, San Jose, CA); and MY9 (CD33), MY4 (CDwl4). and MY7 (CD13) (all supplied by Coulter, Inc, Hialeah, E)]. Background staining was determined using isotype controls (FITC-or PE-conjugated IgGl and PE-conjugated IgG2). After washing, samples were analyzed immediately with a Becton Dickinson FACScan flow cytometer. Although the percent viability of both fresh and thawed, previously cryopreserved leukemic cell suspensions usually exceeded 90%, dead cells were excluded from flow cytometric analysis with propidium iodide gating.I3 Flow cytometric data were analyzed with FACScan software (Becton Dickinson) and results expressed as units of mean channel fluorescence shift relative to background control levels; composite two-color dot plots and contour plots were generated using the Lyses I1 analysis system (Becton Dickinson).
Cytogenetic analysis. Pretreatment BM andlor PB samples were prepared for cytogenetic analysis by direct andor short term (24 to 72 hour) unstimulated cultures at approved SWOG cytogenetics laboratories.15 A minimum of 20 G-banded metaphases were analyzed in each case, and chromosomes were identified and clonal abnormalities classified according to the International System for primer: NCAM residues 2,175 through 2,194 (S'GGCTGTGGG-CTGGGCCGAGG-3')I. The probe was random primed (Boehringer-Mannheim Biochemicals, Indianapolis, IN) and the membrane was hybridized for I hour at 65°C. Stringency washes included one wash of IS minutes at room temperature in 0.1 X SSC, 0.1 o/o sodium dodecyl sulfate (SDS), followed by two 15-minute washes in 0.1 X SSC, 0.1% SDS at 65°C followed by autoradiography.
RT-PCR ussa.ys for promyelocytic (PML)/retinoic acid receptor cu (RARcu) mRNA transcripts. RNA was isolated from 17/20 myeloid/NK leukemia cases with residual cryopreserved cells (all cases except cases 6,9, and 13; Table I ) reverse transcriptase (SO U0.25 pL) (GIBCO-BRL, Gaithersburg, MD), and 7.75 p,L of diethylprocarbonate-treated H20. Five microliters of this reaction was then used for nested RT-PCR assays using primer sequences to detect PML/RARa fusion mRNAs as previously described: M2R8 (M2 derived from PML exon S and R8 from RARa exon 3) to analyze breakpoint cluster regions (bcr) 1 and 2 and M4R8 (M4 derived from PML exon 3) to analyze bcr region 3.2').21 After amplification, 15 p L of the PCR reaction was fractionated and visualized in ethidium bromide-stained agarose gels. Amplification of 02-microglobulin mRNA, using S pL of the cDNA was performed as an internal control for RNA integrity and PCR reaction fidelity in each sample, using an annealing temperature of 5SOC."
RT-PCR assays jiw the promyelocytic leukemia zinc j n g e r (PLZF)/RARa mRNA transcripts. RT-PCR was performed to detect the PLZF/RARa-fusion transcript arising from the t( l l ;17), as previously described." Total RNA (4 pg) from each leukemic sample was hybridized to a primer (5"TGGATGCTGCGGCGGAAG-AAGCCCTTGCAG-3') complementary to the B region of the RARa gene and reverse transcribed by incubation with 200-U MMLV reverse transcriptase (GIBCO-BRL) at 37°C for 45 minutes. One tenth of the cDNA product was then amplified by PCR using Taq polymerase (Promega) in 100-pL volume with a primer complementary to the B region of the RARa (5"GGGCACTATCTC-TTCAG-3' ) and a primer complementary to the B region of PLZF (5"CTGTCTCCATGGACTTC-3' ), with two cycles at 98°C for 5 0 seconds, 47°C for 1.5 minutes, and 72°C for 2 minutes. 32 cycles at 98°C for 25 seconds, 47°C for l .S minutes, and 72°C for 2 minutes.
and a final extension for 12 minutes at 72°C. Ten microliters of the PCR products were electrophoretically separated through a 1.44 agarose gel, transferred to nitrocellulose, prehybridized, and hybridized overnight in 5 X salt sodium phosphate and ethylendiamine tetra-acetate (SSPE), 5 X Denhardt's, 1 mg/mL salmon sperm DNA at 63°C with a radiolabeled oligonucleotide complementary to PLZF (S'-TGGAGCAGCACAGGAAGCTGC-3' ). located 3' to the PLZF amplification primer. After washing, the filters were autoradiographed. A previously identified AML patient with t(1 1;17) and a PLZFRARa-fusion product was used as a positive control.","
In vitro differentiation studies with ATRA. Previously cryopreserved leukemic blasts from four patients (cases 1 I , 14, IS, and 16; Table 1 ) and from two AML-M3 patients with a confirmed t( 15;17) were thawed in 37°C defrosting medium [RPMI 1640; 20% fetal calf serum (FCS)], centrifuged at 1,100 rpm for 5 minutes and then resuspended in complete culture medium (RPMI 1640, 2 0 8 FCS, antibiotics). Cells were cultured with or without l PmolLATRA (Sigma Chemical Co. St Louis, MO) for 7 days as previously described."~?' Aliquots of cells removed at time 0 and days 2, 5. and 7 were analyzed by cytologic evaluation and differential count of Wright and SBB-stained cytospins. Maturation was defined by a gain in cytoplasmic volume, loss of cytoplasmic granularity after the promyelocytic stage, and nuclear segmentation.
I n vitro cytotoxicify ussuys. The cytotoxicity of previously cryopreserved leukemic cell suspensions from six myeloid/NK leukemia cases with residual cells (cases 3, I O [a posttreatment relapse specimen was analyzed as pretreatment cells were not available], 12, 14, IS, and 19, Table I ) was tested in a "Chromium (Cr) release functional assay." An NK leukemia cell line (IMC-I; recently developed in our laboratory) and an AML-M3 sample with a confirmed t( I 5 ; 17) were used as controls.2x Target cells included the NK cell-susceptible K562 (human erythroleukemia) line. Target cells were incubated with "Cr (New England Biolabs, Boston, MA) in I mL of bovine calf serum (BCS) (SO pCi/l X IO" cells) for 2 hours at 37°C in air/ CO2 (19: l). The cells were then washed three times with complete medium (RPMI 1640, 10% BCS, and 50 U of PenicillidmL, 5 0 pg/ mL of Streptomycin, and 50 pg/mL Gentamicin (Sigma). Cryopreserved leukemic cells (effector cells) were defrosted in warm defrosting medium, centrifuged at l , l00 rpm for 5 minutes, and then resuspended in complete media. Effector cells were added ( 5 X I O 5 cells/100 pL for a 50: I ratio) to the wells of round-bottom microtiter plates (Costar, Cambridge, MA), and were diluted at ratios of 25: I (2.5 X 1O5/10O pL), 12.5:l (1.25
X 10'/100 pL). 6.25:l (6.25 X 10'/100pL),and3.12:1 (3.12X lO'/lOOpL).Forassayswhere 12:l was the highest effector:target ratio used, effectors at 1.2 X IO' cells/100 pL were added to the wells and the appropriate dilutions were made. Each ratio was tested in triplicate. Targets were added ( l X 10' cells/100 pL) to each well, and the plate was centrifuged at 501: for 3 minutes and incubated for 4 hours at 37°C (air/COz. l9:l). Effector and target cell mixtures were assayed before incubation with recombinant interleukin-2 (IL-2) (Chiron Corp, Emoryville, CA) to obtain a baseline at day 0. Cells were also assayed after effector cells were precultured for 48 hours with 1,000 UlmL IL-2 and complete media (5% CO2, 37°C). After incubation and removal of the IL-2, the supernatant was collected using a harvesting press (Skatron, Sterling, VA) and counted for radioactivity for 1 minute in a gamma counter. Specific lysis (%) was determined as follows: 100 X [(test cpm -spontaneous cpm)/(maximum cpm -spontane-ous cpm)], with maximum release determined by adding 100 pL of target cells to wells containing 100 pL of 10% Triton X-100.27
Isolation of a nonleukemic CD33+, CD.56+, C D 1 6 normal counterpart cell. NK cells were isolated from PB buffy coats of four healthy blood donors, with a pooled average cell count of 4.7 X 109/L, as previously des~ribed.~~-~' Mononuclear cells were collected by Ficoll-Hypaque centrifugation at 1,360 rpm (400g) for 25 to 30 minutes resuspended in 2 mL of RPMI, and layered on top of an equal amount of FCS and centrifuged again at 800 rpm for 5 minutes to remove platelets. The cell pellet was resuspended in complete medium (RPMI 1640, 20% FCS), plated on plastic petri dishes and incubated overnight at 37°C in a CO2 incubator to remove adherent monocytes. The nonadherent cell fraction was washed and T lymphocytes were removed by incubation with mouse anti-CD3 antibody, followed by rosetting with sheep red blood cells coated with rabbit-antimouse IgG. A second Ficoll-Hypaque centrifugation was performed to remove rosetted T cells and the nonrosetted cell layer was harvested. This NK cell-enriched population was then directly labeled for three-color flow cytometric analysis; cells were stained with purified CD56 antibody (Becton Dickinson), washed, and then labeled with biotinylated goat-antimouse IgG F(ab);. After a blocking step with goat serum, the cells were labeled with FITCconjugated CD33 (Coulter) and PE-conjugated CD16 (Becton Dickinson). After washing with Hanks' Balanced Salt Solution (HBSS), the cells were labeled with streptavidin PE-conjugated Texas Red (RED613) (Life Technologies, Becton Dickinson, San Jose, CA) and then washed and resuspended in HBSS. Cells were initially sorted using forward-angle light-scatter and side-scatter parameters on a Coulter 753 Cell Sorter to select for a small to medium-sized, nongranular population; cells stained with mouse isotype control antibodies were used as a negative control to establish gating parameters. Additional gating was performed on CD56+ and CD33' cells to obtain CD16' and C D 1 6 populations for cytospin morphologic and cytochemical evaluation.
Clinical and outcome data. Clinical data for patients registered on treatment studies SWOG 8600 or 9031 were obtained from SWOG central data base and were subjected to standard SWOG 2 41 procedures for reporting and quality control. Seventeen of these patients were registered on SWOG AML frontline studies (11 on SWOG 8600, 3 on SWOG 9031, and 2 on SWOG 9034); three patients were not ultimately registered on any SWOG treatment study (cases 12, 14, and 15, Table 1 ). Data for patients registered on study SWOG 9034, an intergroup study coordinated by Eastern Cooperative Oncology Group (ECOG), were obtained from the ECOG central data base. Data for patients who were not registered on SWOG treatment studies (cases 12, 14, and 15, Table 1 ) were obtained from the hematologist-oncologist responsible for the patient's care. Overall survival was measured from the day of registration on SWOG treatment study (or the start date of induction therapy for non-SWOG patients) until death from any cause. Relapse-free survival (RFS) was measured from the onset of complete response until relapse or death from any cause, with observation censored at the date of last contact for living patients with no report of relapse. Median durations of survival and R F S were obtained from distributions estimated by the method of Kaplan and Meier.3' The BM differential data listed in Table 2 is based on the local institutional pathology.
RESULTS
Flow cytometric immunophenotypic studies. Pretreatment BM and PB specimens from patients who were candidates for frontline AML treatment studies SWOG 8600, 903 1, and 9034 were reviewed for possible inclusion in this study. Specimens from 350 consecutive patients were examined and flow cytometric analysis of hematopoietic cell surface antigen expression showed 20 cases (6%) with a unique immunophenotypic profile. These 20 cases were characterized by a lack of expression of HLA-DR and by the coexpression of various myeloid (CD33, CD13, CD15) and NK cell-associated (CD56) surface antigens; the detailed immunophenotypic profile in each case is provided in Table 1 . Like AML cases of the FAB M3 subtype, all cases consis- 
(A) Coexpression of CD33-PE (Y-axis) and CD56-TR IXaxis). (B) Expression of CD33-PE (Y-axis) and lack of expression of HU-DR-TR (X-axis). (C) Expression of CD33-PE (Y-axis) and lack of expression of CD16-FITC (X-axis). (D) Expression of CD56-TR (X-axis) and lack of expression of CD16-FITC (Y-axis).
tently lacked expression of HLA-DR. an antigen that is preferentially expressed by myeloblasts and lost during maturation to the promyelocytic Although two cases were positive for CD4, this antigen is not T-cell lineage specific and may frequently be expressed on AML blasts and on a subset of PB monocytes.5.x The absence of T-cell lineage commitment was further confirmed by the lack of expression of the T-cell lineage-associated antigens CD2, CD3, and CD8 and by a lack of clonal rearrangement of genes encoding the T-cell receptor (TCRP, y , 61, and 62; data not shown). All cases were characterized by the expression of the myeloid-associated antigens CD33, CD13, and/or CD1 5; the hematopoietic stem and progenitor cell antigen CD34 was expressed at low antigen density in 6/20 cases ( Table  l) . All cases expressed CD56 (a variantly spliced form of the NCAM)"3"4 at high antigen density and did not express CD16 (the immunoglobulin Fcy receptor). The CD1 la adhesion molecule required for NK cell-mediated cytotoxicity,'5.36 was also expressed at high antigen density in all cases in which it was assessed (Table I , Cases I through 10). Coexpression of CD56 and myeloid-associated antigens (CD33, CD13, and CD15) was confirmed in each case by two-and three-color flow cytometric studies (Fig 1) .
RT-PCR and oligonucleotide probe hybridization assays for CD56 (NCAM). To confirm that CD56, and not a crossreactive epitope, was expressed in the myeloid/NK acute leukemia cases, RT-PCR assays were performed to detect CD56 (NCAM) mRNA transcripts in leukemic blasts. A major 493-bp CD56 (NCAM) PCR product was identified in each of two cases tested (Cases 8 and 15; Table 1 ) (Fig   2A) . The analysis also included the CD56' myeloma cell line 8226/Dox40 used as a high-level positive control and an AML case with very low CD56 expression (1 % by flow cytometry) as a negative control. The identity of this 493-bp product has been previously confirmed by DNA sequencing.Ix Hybridization of the RT-PCR products with an NCAM DNA probe confirmed the specificity of the RT-PCR products (Fig 2B) .
Review of morphologic and cwdlernical features. The referring institutional FAB diagnoses were as follows for the 20 cases: 1 MO/L2, 10 M I , 5 M2, 2 M3, and 2 M4. Upon rereview of BM aspirates and PB smears in each case by the SWOG Leukemia Review Panel, the majority of the cases ( 1 3/20) were noted to have distinct, yet similar morphologic and cytochemical features (which we have chosen to designate myeloid/NK acute leukemia; Table l ). These features included strikingly invaginated nuclear membranes, scant to moderate cytoplasm with fine to moderately coarse azurophilic granules, and weak to moderate finely granular SBB and/or MP0 cytochemical reactivity (Fig 3, A and C) . Although these features were highly reminiscent of AML-M3, particularly the microgranular variant (AML-M3v) ( Fig  3B) , distinct differences were apparent. Whereas occasional myeloid/NK blasts had conspicuous cytoplasmic granules, they were not as prominent as typical AML-M3 blasts; moreover, the pattern of weak or moderate finely granular SBB or MP0 positivity was distinct from the intense and dense SBB and MP0 staining of AML-M3 and M3v (Fig 3D) . Rare myeloid/NK blasts contained Auer rods; bundles of Auer rods (faggot cells) characteristic of FAB M3 were not present. All cases were characterized by a high marrow-blast percentage (median blast cell percentage, 92%; range of 47% to 99%); however, in contrast to cases of AML-M3, increased numbers of marrow promyelocytes were not seen (Table 2) Table 1 ) had morphologic and cytochemical similarities to cases designated as myeloid/NK acute leukemia, the overall features were equally consistent with an M1, M2, or M7 designation in the FAB classification system and these cases are designated in this fashion (Table l) .
Pretreatment clinical characteristics and therapeutic response. Detailed pretreatment clinical characteristics and therapeutic responses are provided in Table 2 . Median age at time of treatment was 48 years (range, 18 to 72 years) with an equal sex distribution (10 women, 10 men). The majority of patients presented with high white blood cell counts at presentation with a median of 75.0 X 109/L (range of 1.0 X 109/L to 328.0 X lo9& Table 2 ). The median PB lymphocyte count was 3,8OO/pL (range, 400 to 15,3OO/pL); 9/18 cases had counts greater than 4,00O/pL (data not shown). Extramedullary disease, including hepatosplenomegaly and lymphadenopathy, was noted in only 5 patients; among 18 patients in whom central nervous system (CNS) involvement was assessed, none displayed evidence of CNS involvement at presentation or relapse. In contrast to AML-M3 patients, less than half of the myeloid/NK leukemia patients had a bleeding diathesis at presentation. Eight cases (Table 2 ) had a mild bleeding diathesis consisting of petechial and/or mucosal hemorrhage, whereas 2 patients displayed disseminated intravascular coagulopathy; 1 displayed a mild bleeding diathesis (case 12, Table 2 ) and 1 a moderate diathesis (case 16, Table 2 ).
Thirteen patients were treated with standard-dose cytosine arabinoside and daunorubicin (8 on SWOG 8600, 3 on SWOG 903 1, and 2 off protocol) and three with standarddose cytosine arabinoside plus idarubicin (2 on SWOG 9034 and 1 off protocol). The other four patients received highdose cytosine arabinoside and daunorubicin on SWOG 8600 (2 with 2.0/g/M2/d X 6 days and 2 with 3.0/g/M2/d X 6 days). Eleven patients achieved complete remission (CR).
In five of these cases, relapse occurred after 90 days, 98 days, 15 months, 16 months, or 27 months; the other six patients remain alive without report of relapse at 28 days, 112 days, 16 months, 24 months, 42 months, and 59 months after achieving CR. Eleven patients have died and the other nine remain alive at between 28 days and 65 months (median 16 months). The estimated median survival is 30 months.
Cytogenetic review.
Pretreatment cytogenetic studies were available for 16/20 cases and 12 of these cases had no detectable cytogenetic abnormality (Table 1) . A balanced reciprocal t( 15;17)(q22;ql1-21) is a characteristic feature of acute promyelocytic leukemia (APL; A M L -M~M~v ) and is detectable in 50% to 70% of APL cases by standard karyotypic analy~is.~' However, despite the morphologic and immunophenotypic similarities between our cases and AMLM3v, no case contained a t(15;17) on routine cytogenetic analysis (Table I) . Two cases had karyotypic abnormalities involving chromosome 17q ( with morphologic features most consistent with FAB AML-M7 was characterized by a 47,XY,+8,t(16;21)(pl l;q22), whereas case 10 contained a t(ll;l4)(pl3;qll) (Table l ) .
RT-PCR screerxfor the PML-RARa fusion transcript. Because of the morphologic and immunophenotypic similarities of our cases to A M L -M~v and because of the preponderance of 46,XY or 46,XX karyotypes, we were concerned that the t( 15; 17) might have been missed in routine cytogenetic analysis. Therefore, we used RT-PCR assays to screen RNA isolated from 17 of 20 cases with residual cells (all cases except 9, 13, and 19; Table 1 ) for the PML/RARa chimeric transcript which arises from the t( 15;17). All RNA samples from myeloid/NK cases and from three APL cases with confirmed t( 15; 17) used as controls contained amplifiable 02-microglobulin transcripts (Fig 4A) . In contrast to APL/FAB-M3 cases (Fig 4, B and C, lanes 12 through 14) , all 17 of the myeloid/NK leukemia cases analyzed lacked the PML/ RARa fusion mRNA (Fig 4, B and C, lanes 2 through 1 1 ; data on remaining cases not shown), confirming that myeloid/NK acute leukemia cases are genetically and molecularly distinct from APL/AML-M3.
RT-PCR screen ,for the PLZFiRARa fusion transcript. The AML-associated t( 1 1 ; 17)(q23;q2 1.1) has recently been cloned and characterized.*' Like cases of true APL with a t( 15; 17), the t ( 1 1 ; 17) involves the RARa gene in the same intron on chromosome 17q21; but in contrast to APL, the t( 11;17) results in a fusion of RARa with a novel gene designated PLZF on chromosome 1 1q23.23 As one of our cases had a cytogenetically detectable t( 1 1 ; 17)(q2 1 ;q23) (case 16; Table l), we wanted to test for the presence of the PLZF/RARa fusion transcript in this case, and to determine whether any of the other cases (particularly those with 46,XX or 46,XY karyotypes) contained a PLZF/RARa fusion mRNA. RT-PCR for the PLZFIRARa fusion mRNA, as shown in Fig 4D, detected a 319 -bp PLZF/RARa product in our case with a t( 1 1;17) (Fig 4D, lane 12) as well as in a positive control sample. However, none of the eleven other myeloid/NK acute leukemia cases tested expressed this fusion product (Fig 4D) . Thus, although the t( 11;17)(q23;q21) appears to be associated with the myeloid/NK leukemia cell phenotype, other genetic abnormalities, yet to be defined, must be present in the majority of the myeloid/NK acute leukemia cases.
Response of cases to ATRA-Induced differentiation. A hallmark of APL with t(15;17) and the PMLIRARa fusion transcript is an induction of differentiation in vitro and in vivo in response to ATRA."-4' The in vitro responsiveness of AML cases with t ( 1 1;17) to ATRA has not been previously determined. Because of the morphologic and immunophenotypic similarity of our cases to APL and the inclusion of one case with a t( 1 1;17)(q23;q21) involving the RARa gene in our series, we sought to determine the responsiveness of myeloid/NK acute leukemia cases to ATRA in vitro. Residual cryopreserved cells from six patients (Cases 3, 11, 14, 15, 16, and 19; Table l), all of whom had Ficoll-Hypaqueenriched cryopreserved blast cell percentages exceeding 90%, and two control cases of APL/AML-M3 were cultured in vitro in medium with or without ATRA. Morphologic differentiation was assessed at time 0 and on days 2,5, and 7 postculture. ATRA-induced granulocytic differentiation was observed in none of the six myeloid/NK acute leukemia or increased cytotoxicity compared with freshly isolated PB cases, including case 16 (Table I ) with a t(l1;17) (data not NK cells'* (Fig 5) . NK cell-mediated cytotoxicity was also shown). In contrast, both control APL/AML-M3 cases analyzed in two cases of APL with a confirmed t( l5;17) (Fig showed myelocytic differentiation with decreased blast per-5). Four cases (cases 3, IO, 14, and 19; Table 1 ) displayed centages at days 5 and 7 (data not shown). These results significant cytotoxic activity with IL-2, as compared with further support the distinct biologic nature of myeloid/NK the positive NK leukemia control cell line (Fig 5; showing acute leukemia and confirm the nonresponsiveness of these the data from case 14). In contrast, both cases of APL/FAB cases to ATRA in vitro.
M3 lacked cytotoxic activity (Fig 5) . This demonstration of Assessment of N K cell-mediated functional cytotoxicity.
functional cell-mediated cytotoxicity in the leukemic cells Because the myeloid/NK acute leukemia cases coexpressed further supports a relationship between myeloid/NK acute the CD56 and CD1 la antigens essential for functional NK leukemias and cells derived from the NK lineage. cell-mediated cytotoxicity in addition to sharing the CD56', Isolation of a CD33', CD%', C D 1 6 nonleukemic coun-CD16-phenotype of NK precursor cells, we sought to deterterpart cell. Although our myeloid/NK acute leukemia mine whether these leukemic cases displayed functional NK cases expressed the CD56', CD16-phenotype of NK precell-mediated cytotoxicity.""" Cytotoxicity was assessed in cursor cells, they also coexpressed the myeloid-associated a standard "Cr release functional assay using the NK cellantigen CD33. As previous studies characterizing CD56+, susceptible line K562 as a target cell (Fig 5) . Leukemic CD16-NK precursor cells have not included an analysis of blasts from six cases [cases 3, I O (results obtained with myeloid antigens such as CD33,42-4h we sought to determine relapse material), 12, 14, 15, and 19; ( Table l) ] were added whether the coexpression of CD33 in our cases reflected an as effector cells; in each case selected for analysis, the leukeaberrant leukemic phenotype or whether a CD33', CD56', mic blast cell percentage in the enriched cryopreserved cell CD16-rnyeloid/NK cell was present in normal BM and suspensions exceeded 90% and no cells with LGL morphol-PB. Using PB buffy coats from four healthy donors, a threeogy were evident in the preassay or postassay samples. The step isolation process was performed to enrich for NK cells. levels of cytotoxicity in these leukemic samples were comCells obtained by these methods were labeled with CD33, pared with those of a positive control cell line, the IL-2-CD56, and CD16 antibodies and sorted using multiparamedependent IMC-I NK leukemia cell line that displays equal ter flow cytometry. From plots of forward-angle light scat- 
DISCUSSION
We have characterized a previously unrecognized form of acute leukemia with unique morphologic, immunophenotypic, cytogenetic, and functional biologic features. These 20 adult de novo acute leukemia cases were characterized by the coexpression of myeloid-associated (CD33, CD13, CD 15) and NK cell-associated (CD56) antigens and the lack of expression of HLA-DR and the T-cell-associated antigens CD3 and CD8. Despite their morphologic and immunophenotypic similarity to cases of APL/FAB M3v, these cases lacked the t( 15; 17) and the resultant PML/RARa fusion transcript. Furthermore, no case showed a differentiation-induction response to ATRA in vitro, in contrast to cases of true APL with the PML/RARa fusion transcript. We suggest that these acute leukemia cases may account for some cases of APL that have not responded to ATRA.23.3y~40 Because these CD33+, CD56+, CD16-acute leukemias showed functional NK cell-mediated cytotoxicity and because we were able to identify a normal CD33+, CD56+, CD16-counterpart cell in the PB of healthy individuals, we further suggest these acute leukemia cases may arise from transformation of a precursor cell common to the myeloid and NK cell lineages. Therefore, we have chosen to designate this type of leukemia as myeloid/NK acute leukemia.
Historically, NK cell leukemia has been considered a subset of LGL lymphoproliferative disorders, characterized by an indolent or chronic clinical co~rse.~' It seems inappropriate to include myeloid/NK cell acute leukemia, a more aggressive disease with a distinct non-T-, non-B-cell immunophenotype, as a subtype of this disease. True human NK cell-lineage acute leukemias are rare; to date, only a few well-characterized cases have been reported in the literat~re.".~' Until recently, the literature regarding LGL disorders has been confusing, partly because of numerous proposed classification schemes and to a paucity of detailed molecular, genetic, and immunophenotypic data. In a recent review,'" Loughran provides a basis for a uniform classification of LGL disorders that is based on reproducible clinical and clonal features: LGL disorders are divided into three distinct subgroups designated T-LGL leukemia (clonal CD3+), NK-LGL leukemia (clonal CD3-), and LGL lymphocytosis (nonclonal CD3' or CD3-). The myeloid/NK acute leukemias that we describe in this report are most similar to the NK-LGL subgroup." However, whereas the acute clinical presentation, equal sex distribution, and CD3-clonality of NK-LGL leukemia may resemble myeloid/NK acute leukemia, comparison of other features shows that these two diseases are distinct. Although 9/18 of the myeloid NK leukemia cases had a mild to moderate absolute increase in PB lymphocytes, only rare cases showed an absolute increase in PB and BM cells with LGL morphology. In contrast, NK-LGL leukemia consistently presents with an absolute lymphocytosis (greater than 4,0OO/pL) and displays frequent and rapid increases in LGL counts (greater than 50,000/pL).50 Coagulopathy is also more common and severe in NK-LGL le~kemia.~" Other features not shared with myeloid/NK acute leukemia include massive hepatosplenomegaly and involvement of the gastrointestinal tract with jaundice and ascites. The characteristic morphologic feature ter versus side scatter, a population of intermediately-sized cells with low side scatter (Fig 6A, see page 249 ) was selected for flow cytometric sorting using a Coulter 753 flow cytometer. From these sorting experiments, a population of CD33+, moderately bright CD56+, CD16-cells was obtained in each sample (Fig 6, B and C) . Previous studies4* that used FACscan flow cytometry with log scale of 4 have shown that CD16-NK cells are predominantly CD56 brightly positive. The use of log 3 data in our study, as compared with log 4 data, tends to compress the data toward the X-axis and therefore the flourescence intensity shift does not appear to be as great. Based on the sensitivity of the Coulter 753 flow cytometer and the log 3 scale setting, although our data cannot be directly compared with Lanier's study, we believe that our data is consistent with the findings of that study. We calculate these cells to be present at a frequency of approximately 1% to 2% of PB mononuclear cells in healthy adults. The morphologic and cytochemical features of the sorted CD33+, CD56+, CD16-population showed features of NK or LGLs with irregular or invaginated nuclear membranes with coarsely clumped chromatin and abundant slightly basophilic cytoplasm containing scattered small azurophilic granules. These cells did not stain with nonspecific esterase stains (data not shown), distinguishing them from CD56+ monocytic cellsu Comparison of the morphologic features of these normal sorted CD33+, CD56+, CD16-PB cells (Fig 6D) to those of the CD33+, CD56+, CD16-leukemic cells (Fig 3A) show striking similarities: moderately high nuclear to cytoplasmic ratios, irregular nuclear membrane contours, and scant azurophilic cytoplasmic granulation. These data confirm the presence of a normal CD33', CD56+, CD16-myeloid NK cell population in the PB of normal individuals.
of NK-LGL leukemia is the presence of increased PB and BM cells with LGL morphology with or without coarse cytoplasmic granules, rather than the unique blast cell features of myeloid/NK acute leukemia. The immunophenotype of NK-LGL leukemia (CD3-, CD56+, CD25-, CD16+, and CD579 is also distinctly different from myeloid/NK acute leukemia. Although expression of stem cell, myeloid-associated, and adhesion molecules have not yet been thoroughly studied in NK-LGL leukemia, the HLA-DR+/CD56+ NK-LGL leukemia cases reported by I m a m~r a~~ were CD13-and CD33-negative, supporting our theory that NK-LGL leukemia and myeloid/NK acute leukemia are separate and distinct diseases. In contrast to myeloid/NK acute leukemia, many clonal NK-LGL cases have been reported to have simple or complex abnormalities of chromosome 5.50*5' Finally, in contrast to the majority of our myeloid/NK acute leukemia cases, most NK-LGL leukemia patients have had rapidly progressive clinical courses and have died within several months of presentation despite aggressive treatment. Thus, although the myeloidrNK acute leukemias that we present in this report and cases of NK-LGL leukemia have some shared features and both may be related to the NK cell lineage, distinct biologic and clinical differences are apparent.
All myeloid/NK acute leukemia cases expressed the CD56 antigen at high density. CD56 is an isoform of the wellcharacterized NCAM that mediates celVcell adhesive intera c t i o n~.~~.~~.~ CD56+, CD16+ NK cells express a variantly spliced form of CD56 that mediates NK cell-target Expression of CD56, in addition to the CD1 l a adhesion molecule also expressed on myeloid/NK acute leukemia cases, is required for NK cell-mediated cytotoxic effector function.36. 44 In addition to the characteristic expression of CD56 on normal NK cells, CD56 is also expressed on a subset of CD3+ cytotoxic T cells, and a subset of PB monocyte~.~~.'"' In hematopoietic neoplasms, CD56 has also been detected on clinically aggressive T-cell lymphomas, plasma cell myelomas, and de novo AMLs with t(8;21), t(8;16), and other monocytic leukemia-associated cytogenetic abnorm a l i t i e~. '~*~~-~~ The forms of CD56 expressed by various hematopoietic neoplasms are highly variable as a result of both alternative splicing and differential glyc~sylation'~; these alternative isoforms may account in part for the different biologic behaviors of CD56' neoplasms.
Expression of CD16 is not uniform in cells of NK lineage and is not necessary for NK cell function. In contrast to initial reports of diminished cytotoxicity of CD56', CD16-NK cells, subsequent studies have shown that CD56+, CD16-NK cells may have increased cytotoxi~ity.4*.~~~~~ Thus, the lack of expression of CD16 in our cases does not preclude NK cell lineage and the cytotoxicity shown by our CD33+, CD56+, CD16-, CDlla+ cases is not unexpected. Although the majority of PB NK cells coexpress CD56 and CD16, a CD56+, CD16-NK cell population has been identified at frequency of less than 2% in normal PB.43,46 It has been suggested that CD56+ NK cells that are CD16-or CDi6'" are NK cell precursors because these CD56+, CD16-cells comprise the majority of NK cells found in the BM and splenic pools.44,46 Natural killer cells with a similar phenotype have also been generated from primitive CD34', HLA-DR-progenitors in long-term BM cultures supplemented with IL-2.45 Unfortunately, the coexpression of myeloid-associated antigens has not been examined in most NK cell studies; thus, we cannot determine whether the CD56', CD16-NK precursor cells identified in those studies correspond to or are distinct from the CD33+, CD56+, CD16-leukemic cells that we have identified in this report. As NK cells are known to be BM-derived, we speculate that the normal CD33+, CD56+, CD16-cells that we have identified may be a precursor population common to the myeloid and NK cell lineage.45 It will be interesting to determine the growth factor dependence of these cells in future studies, and whether the CD33 antigen is lost upon culture of these cells with IL-2 that may promote further differentiation into the NK lineage. Finally, we speculate that the CD33+, CD56+, CD16-acute leukemias that we have identified may represent leukemic transformation of this normal CD33+, CD56+, CD16-normal counterpart cell.
Despite morphologic and immunophenotypic similarities, myeloid/NK acute leukemia cases lacked the t( 15;17) and failed to show a differentiation-induction response to ATRA in vitro. Distinguishing these myeloid/NK acute leukemias from cases of true APL will be important for clinical studies of ATRA. De Rossi et a13* have proposed that immunophenotypiclflow cytometric analysis could be used to make a precise diagnosis of APL; the diagnostic profile proposed was CD33+, CD13+, CD9+
(a B-cell and granulocytic marker), HLA-DR-, and CD7-. Unfortunately, the immunophenotypic studies presented in this report show that this profile would not distinguish cases of true APL from myeloid/NK cell acute leukemia cases. Our studies suggest that myeloid/NK cell acute leukemias could be distinguished from cases of true APL by inclusion of the CD56 and CD16 antigens in the proposed diagnostic panel. However, this immunophenotypic approach may still not allow precise diagnosis; in a review of the immunophenotypic data of 50 SWOG APL/AML-M3 cases [(with a confirmed t(15;17)], we identified two APL cases with expression of CD56 at high antigen density (data not shown). Thus, we propose that all acute leukemia cases with morphologic features similar to APL be initially analyzed by flow cytometric immunophenotyping using a panel that includes the HLA-DR, CD34, CD33, CD15, CD16, CD56, and CDlla antigens, and by careful morphologic examination with rigid adherence to criteria for A M L -M~N~V .
Diagnostic confirmation of APL versus myeloid/NK acute leukemia should include RT-PCR studies to assess the presence or absence of the PMWRARa fusion transcript. With the morphologic and immunophenotypic similarity of myeloidlNK acute leukemia cases to APL, it is of interest that one of our myeloid/NK acute leukemia cases was associated with a t( 1 1 ; 17)(q23;q2 1) that results in fusion of the RARa and PLZF genes.23 PLZF has some homology with the zinc finger gene MZFl and is a putative transcription factor preferentially expressed by myeloid cells.23 Although the t(11;17) was initially cloned from a case of APL, our myeloid/NK acute leukemia patient with t( l 1 ; 17) did not have features of APL.23-24 Morphologically, this patient was classified as M2 by FAB criteria and had 10% promyelocytes in the BM. The patient did not respond to chemotherapy, nor did the patient's cells respond to
